Tarsus Pharmaceuticals Inc (TARS)
46.65
+0.15
(+0.32%)
USD |
NASDAQ |
Nov 14, 16:00
46.49
-0.16
(-0.34%)
After-Hours: 16:50
Tarsus Pharmaceuticals Gross Profit Margin (Quarterly): 92.64% for June 30, 2024
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 92.64% |
| March 31, 2024 | 94.01% |
| December 31, 2023 | 90.70% |
| September 30, 2023 | 79.85% |
| June 30, 2023 | |
| March 31, 2023 | |
| December 31, 2022 | 96.00% |
| Date | Value |
|---|---|
| September 30, 2022 | |
| June 30, 2022 | 96.58% |
| March 31, 2022 | 93.88% |
| December 31, 2021 | |
| September 30, 2021 | 94.76% |
| June 30, 2021 | 96.65% |
| March 31, 2021 | 96.12% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
79.85%
Minimum
Sep 2023
96.65%
Maximum
Jun 2021
93.12%
Average
94.38%
Median
Gross Profit Margin (Quarterly) Benchmarks
| Amicus Therapeutics Inc | 90.62% |
| CEL-SCI Corp | -- |
| AIM ImmunoTech Inc | 84.00% |
| IGC Pharma Inc | 59.93% |
| NovaBay Pharmaceuticals Inc | 66.33% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -69.10% |
| Return on Assets | -51.79% |
| Return on Invested Capital | -59.01% |
| Profit Margin (Quarterly) | -81.57% |
| Operating Margin (Quarterly) | -81.60% |
| Return on Net Operating Assets | -465.7% |